Nuvalent
a rationally designed selective sparing inhibitor medical needs preliminary phase conclusions activity mutant activity approved approved approved investigational activity i activity observed in patients with i i including after exhausting approved and investigational therapies such as and mutant activity activity observed in patients with resistance mutations activity key observed in clinical investigation activity avoiding patients activity observed in patients with history of metastases including intracranial responses in with emerging safety profile was consistent with design with no dose reductions or treatment discontinuations due to adverse events source head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
February 2024
Slide
29 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
a rationally designed selective sparing inhibitor medical needs preliminary phase conclusions activity mutant activity activity avoiding approved approved approved investigational activity i activity observed in patients with i i including after exhausting approved and investigational therapies such as and mutant activity observed in patients with resistance mutations activity activity observed in patients with history of metastases including intracranial responses avoiding emerging safety profile was consistent with design with no dose reductions or treatment discontinuations due to adverse events key observed in clinical investigation source head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Investor Presentation
January 2024
a rationally designed selective sparing inhibitor medical needs preliminary phase conclusions approved approved approved investigational by activity mutant activity activity key observed in clinical investigation activity observed in patients with including after exhausting approved and investigational therapies such as and activity observed in patients with resistance mutations activity mutant activity activity activity observed in patients with history of metastases including intracranial responses avoiding emerging safety profile was consistent with design with no dose reductions or treatment discontinuations due to adverse events source head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Investor Presentation
January 2024
a rationally designed selective sparing inhibitor medical needs preliminary phase conclusions approved approved approved investigational by activity mutant activity activity key observed in clinical investigation activity observed in patients with including after exhausting approved and investigational therapies such as and activity observed in patients with resistance mutations activity mutant activity activity activity observed in patients with history of metastases including intracranial responses avoiding emerging safety profile was consistent with design with no dose reductions or treatment discontinuations due to adverse events source head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Related slides by other companies
Kymera
Investor Presentation
August 2023
part summary | Kymera
Apollomics
SPAC
September 2022
activity in a patient with primary lesions and brain metastasis | Apollomics
BenevolentAI
Investor Conference
January 2023
using our platform for societal bene a covid treatment now approved for use by the non commercial collaboration rapid novel effective focused on dengue fever a major burden aims to deliver biological targets and drug candidates experimental validation in progress assays benefit lilt | BenevolentAI
Kymera
Investor Presentation
December 2023
partial response and stable disease observed across multiple tumor types during dose of | Kymera
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io